Spiegel H U, Scommotau S, Uhlmann D, Giersch B
Department of General Surgery-Surgical Research, Westfaelische Wilhelms-Universitaet, Muenster, Germany.
Zentralbl Chir. 1996;121(9):788-93.
One mechanism evoked by ischemia is endothelin mediated vasoconstriction of the hepatic vascular bed. Postischemic sinusoidal constriction leads to microcirculatory disturbances and reduced blood flow, thereby causing local hypoxia and liver damage. The aim of the study was to avoid the constrictive response of sinusoids by blocking endothelin receptors.
In an in vivo ischemia-reperfusion-model (21 Wistar rats, 250-300 g) with portal decompression by a splenocaval shunt, hepatic ischemia was induced for 30 min by cross clamping of the hepatoduodenal ligament. The effect of the endothelin receptor antagonist bosentan (10 mg/kg bw i.v.) injected before ischemia was assessed by in vivo microscopy. Microhemodynamic studies, including the sinusoidal perfusion rate, diameters of hepatic sinusoids and postsinusoidal venules, leukocyte endothelium interactions and leukocyte velocity were performed.
After ischemia sinusoidal diameters and diameters of postsinusoidal venules were significantly reduced to 76 +/- 7% and 86 +/- 10%, respectively, in the non-treatment group, but dilated to 109 +/- 6% and 118 +/- 8% in the group treated with endothelin receptor antagonist (p < 0.001). Increased percentage of postischemic permanent adherent leukocytes could be diminished in sinusoids and more markedly in venules by therapy (p < 0.001). Leukocyte velocity was decreased to 69 +/- 9% in the treatment group ( p < 0.001). Perfusion rate could be improved to 90 +/- 2% compared to 83 +/- 5% in the untreated group (p < 0.01). Systemic arterial blood pressure was not affected by administration of the receptor antagonist.
These data indicate that the endothelin receptor antagonist treatment results in prevention of postischemic sinusoidal constriction. Perfusion rate could be improved due to dilation of sinusoids and diminished leukocyte adhesion, but leukocyte velocity was reduced by 31%.
缺血引发的一种机制是内皮素介导的肝血管床血管收缩。缺血后肝血窦收缩会导致微循环紊乱和血流减少,进而引起局部缺氧和肝损伤。本研究的目的是通过阻断内皮素受体来避免肝血窦的收缩反应。
在一个通过脾肾静脉分流进行门静脉减压的体内缺血再灌注模型(21只体重250 - 300克的Wistar大鼠)中,通过夹闭肝十二指肠韧带诱导肝脏缺血30分钟。在缺血前静脉注射内皮素受体拮抗剂波生坦(10毫克/千克体重)的效果通过体内显微镜检查进行评估。进行了微血流动力学研究,包括肝血窦灌注率、肝血窦和血窦后小静脉直径、白细胞与内皮细胞相互作用以及白细胞速度。
在非治疗组中,缺血后肝血窦直径和血窦后小静脉直径分别显著减小至76±7%和86±10%,但在内皮素受体拮抗剂治疗组中分别扩张至109±6%和118±8%(p < 0.001)。治疗可使缺血后肝血窦中永久性黏附白细胞的百分比增加减少,在小静脉中更显著(p < 0.001)。治疗组白细胞速度降至69±9%(p < 0.001)。与未治疗组的83±5%相比,灌注率可提高至90±2%(p < 0.01)。受体拮抗剂的给药未影响全身动脉血压。
这些数据表明内皮素受体拮抗剂治疗可预防缺血后肝血窦收缩。由于肝血窦扩张和白细胞黏附减少,灌注率得以提高,但白细胞速度降低了31%。